Codexis Selected for Third Presidential Green Chemistry Award in Seven Years
News Jun 19, 2012
This marks the third time in seven years that Codexis has been honored with this award; Codexis was a recipient in 2006 and 2010.
Simvastatin is the most prescribed statin in the U.S., with 94.1 million prescriptions in 2010 according to IMS Health. Traditionally, synthesis of simvastatin has required an inefficient, multistep chemical process that involves significant quantities of hazardous reagents. In collaboration with Professor Yi Tang at the University of California, Los Angeles, Codexis conceived and developed a synthesis using an engineered enzyme and a practical, low-cost feedstock. Codexis optimized both the enzyme and the chemical process for the large-scale, commercial manufacture of simvastatin. The resulting process produces high quality simvastatin in a cost–effective manner and greatly reduces the use of hazardous chemicals and the amount of waste produced.
“Collaborating with the Codexis team was a true inspiration. Their directed evolution technology empowered us to go beyond academic theory and deliver a more environmentally friendly process that is impacting the pharmaceutical industry today,” said Yi Tang, Professor, University of California Los Angeles.
“Green chemistry and Codexis’ CodeEvolver™ directed evolution technology represent the future of cleaner, more efficient, and cost-advantaged pharmaceutical manufacturing processes. With the help of Professor Tang and his team, this award confirms Codexis’ role as an industry leader, and we are honored to be recognized for a third time by the U.S. Environmental Protection Agency (EPA) for our achievements,” said Gjalt Huisman, Ph.D., Vice President of Product Planning, Pharmaceuticals at Codexis.
The process was scaled up at Codexis’ longstanding collaborator, Arch Pharmalabs Ltd., in Mumbai, India. Arch Pharmalabs manufactures a number of products for Codexis, including the 2006 Presidential Green Chemistry Challenge Award-winning process for atorvastatin, the active ingredient in Pfizer’s Lipitor®.
“We are running six biocatalytic processes developed by Codexis and have shown that they are reliably scalable and comparable to chemical processes, while offering significant advantages in terms of product purity, reduced waste, and reduced energy consumption,” said Dr. Ganesh Pai, Director of Research and Development, Arch Pharmalabs Ltd.
Codexis is the first and, to date, only company to have won the Presidential Green Chemistry Challenge Award in both the small business and open categories. In 2010, in collaboration with Merck, Codexis won a previous Green Chemistry award for the development of a novel biocatalytic method for the synthesis of sitagliptin, the active pharmaceutical ingredient in Merck's Januvia®. And in 2006, as a small business with less than $40 million in annual sales, Codexis was similarly honored for developing three enzymes used to produce the key chiral building block for atorvostatin.
Researchers Develop New Method to Generate Human AntibodiesNews
Researchers hope their approach will help researchers rapidly generate therapeutic antibodies for the treatment of infectious diseases and other conditions such as cancer.READ MORE
Large-Scale Production of Living Brain Cells Enables Entirely New ResearchNews
After performing a biopsy on the patient, the skin cells are transformed into brain cells that effectively imitate the disease and the age of the patient.READ MORE
U.S. Study of Dapivirine Ring in Lactating Women Finds Little Drug Gets Into Breast MilkNews
The antiretroviral drug dapivirine that is released from an experimental vaginal ring to protect against HIV is absorbed in very low concentrations into breastmilk.READ MORE
Comments | 0 ADD COMMENT
EMBL Conference: European Conference of Life Science Funders and Foundations
Apr 19 - Apr 20, 2018
EMBL Course: Target Engagement in Biology and Drug Discovery
Feb 19 - Feb 23, 2018